Optibiotix Health Share Discussion Threads

[elrico] 29/8/2017 19:25

Slarty - Shorting is something I generally avoid because there is something morally repugnant about it, especially within the small cap arena where a company is trying to establish a commercial market and may need funds for the final push. I have only shorted 4 companies in 30+ years and ALL have been subject to fraudulent activities and to my mind, fair game. I accept there is an issue for investors, but to my mind they remain invested despite facts in the public domain and therefore subject to their own stupidity. As for shorting RANK, you know they are my employers biggest client, so this has another moral and professional implications for me. I am not going to get involved with the why's, wherefore and merits of going short.

Chin up fella, Chelski have found their mojo again. ;)

[slartybartfaster] 29/8/2017 19:10

You like a short don't you elrico. You know it makes sense.

[joyjoy13] 29/8/2017 18:55

Good to see were holding in the 70's, very promising.

Yes, world markets very volatile at the moment, foreign stuff and our Britex stuff....

I my optimisum, I am assuming, IMHO, that Opti will be immune to such worldwide influences once were fully fledged.
Currency markets/exchanges shouldn't off balance us as we're getting globally based. And our "products" are needed by all nations for their health benefits.

Just my ramblings but I think we're well placed to avoid such influences ...
P.s. Only my AIM stock faired well today, other FT350 all down.
Delighted Opti, though down, held above the 70 range.

Bear in mind a lot of folk still avoid the summer stagnate months on the stock exchange and come back in September...
What's that saying,
Sell in May?

GLA

[slartybartfaster] 29/8/2017 18:53

Go short of RNK. They are suffering with dwindling footfall and the new money laundering legislation and now losing staff due to brexit. I work in one of the London casinos. They want staff to cover overtime but the new contracts don't pay overtime until the 49th hour. Staff moral is at an all time low. They have done all the penny pinching they can, now no wriggle room.

[bdog51] 29/8/2017 18:35

Entirely Red portfolio today thanks to Mr kim jong un. All things considered, OPTI held up pretty well whilst the rest of the markets panicked, as they generally do when NK do their crazy stuff.

[monkeywench1] 29/8/2017 18:06

Sold out!!

[parob] 29/8/2017 18:04

Lactobact LDL-Control now available on eBay.co.uk

Easy to order for those with a UK eBay account - and a good price:

[onedayrodders] 29/8/2017 16:40

Nice if only modest buying into the close

[adnanwolf] 29/8/2017 14:25

This is the abstract for the new drugExperimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.METHODSWe conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1?, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death.RESULTSAt 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31).CONCLUSIONSAntiinflammatory therapy targeting the interleukin-1? innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.)The absolute risk reduction was 0.64% which is pretty small and so the number of patients that would need to be treated to prevent 1 heart attack etc would be 100/0.64 which is 156This would cost 6 million pounds. Even assuming cost is much smaller for the NHS it is still substantial. I can't see NICE approval except for a very small number of high risk patients with a high CRPAdnan

[parob] 29/8/2017 12:14

More cognitive studies coming out of University College Cork:

[mikerobe1] 29/8/2017 11:42

Jeremy vine midday discussing amongst other things antidepressants and gut bacteria.

[rafboy] 29/8/2017 11:28

Morning all, still on holiday? I thought the publicity on the new heart drug over the weekend gave a good indication of the press attention we might receive once we are selling our LDL and cholesterol products in UK.

[lukead] 29/8/2017 09:04

Oh thanks MichaelMouse, you are a good chap, some of the time........,

[michael1mouse] 29/8/2017 08:50

Interims october.

[michael1mouse] 29/8/2017 08:49

The first myth being pushed by some, including we are ashamed to say one writer at ShareProphets, is that having a couple of RNS's releases is a prelude to a fund raise. After a month or two of silence for a company as busy as this one to have a couple of announcements is hardly startling is it? Optibiotix plays by the rules and announces news when it is ready to be announced not as part of some cunning PR offensive. Moreover...

We remind you of what the company said in April: "Cashflow remains tightly controlled with a focus on building shareholder value through investment in R&D, and adding to our in-house and out-house IP. The Groups cash position remains strong at £3,115,366 (2015: £2,040,888) which is sufficient to fund its existing research and development programmes, extend technology platforms into other product and application areas, and support the sales and marketing of our pipeline of products."

The company's cash burn is not great because it develops IP that others then produce product from paying Optibiotix back a royalty stream. So this company can scale up sales without any capex or indeed working capital draw. The cash pile is not going to be that much lower four months after that last statement. Indeed as sales pick up the move towards the inflexion point of achieving cash breakeven becomes ever closer. So THERE IS NO PLACING.

[michaelmouse] 29/8/2017 07:33

Your turn next? Where are the interims?



Have a nice day.

[nimrod22] 28/8/2017 23:26

At least my gold/silver holdings are going up since Kim Jong-un has started this evening.Lets see how shares make out tomorrow.

[slartybartfaster] 28/8/2017 21:44

If this isn't talkingtrades i'm a gooner.



A man loses half a million quid on shares now wants to bet his last £280,000 on 1 stock to double or treble.

ok, probably have to take a 0 off the number.

[adnanwolf] 28/8/2017 21:43

I saw that as well. Unfortunately costs £40k per patient per year. Use will very very limited. Totally different market to our products GLA too all LTHAdnan

[diamond fibre] 28/8/2017 18:00

Front of the Sunday mail is very interesting, lucky for us we have more strings to our bow.

[joyjoy13] 28/8/2017 14:02

Parob,
Well, your doing a sterling job.
Hope you managed to get your average down after recent dips.
Been great opportunity to top up, do feel,IMHO, were definitely on that tipping point.
Good luck

Might quote Dell Boy.....
This time next year Rodders, we'll all be millionaires...

Well, happened, they did! Chuckle.
Anyhow, time will tell and I'm just so happy got under under a £1.
The way the news is these days, every day nearly filled with articles about how the nation is overweight, cholesterol, high blood pressure... Probably more due to fact life more stressful these days...but that's another topic....
But I feel like we're definitely in the right market (s) at this point in time with regards global health issues......

[rafboy] 28/8/2017 13:12

yes, thanks parob, very informative.

[parob] 28/8/2017 12:52

Joyjoy13, you're welcome. When you have so much invested, you watch every move like a hawk. Happy to share any research.Sacco probably realise LP-LDL could be one of their biggest earners.Not surprised they've agreed to support the funding of further marketing and human studies in return for 50% of the profit.

[asterix96] 28/8/2017 11:03

Outside America, spelt is more common, but spelled is generally accepted. (This is almost certainly a result of American influence spreading.)

[onedayrodders] 28/8/2017 10:40

Asterix9627 Aug '17 - 19:56 - 26477 of 26485

ADVFN spellchecker doesn't like "spelt"